Abstract 4928: Immune signaling reporter cell lines enable quantitative monitoring of crosstalk among cancer, innate, and adaptive immune cells in tumor microenvironment model

Abstract Background: T cell-targeted immunotherapies have led to major clinical gains, yet many patients fail to respond or develop resistance due to the immunosuppressive tumor microenvironment (TME). Increasing evidence shows that B cells and myeloid cells also influence antitumor immunity, but accessible models capable of capturing interactions among cancer cells and multiple immune cell types remain limited. To address this gap, we developed immune signaling reporter cell lines that allow real-time, quantitative monitoring of NFAT- and NF-κB-driven activation pathways. These models enable capturing dynamic interactions among multiple immune cell lineages and cancer cells relevant to immunotherapy response. Methods: Six luciferase-based reporter lines derived from T cells, B cells, or myeloid cells were engineered with NFAT or NF-κB response elements driving luciferase expression. The models retain high endogenous expression of checkpoint receptors, including PD-1, TIGIT, and GITR in T cell reporters and SIRPα, Siglec-10, LILRB1, and B7-1 in myeloid reporters. Reporter activation was assessed following pathway-specific stimulation: PMA and ionomycin for NFAT and TNF-α or T cell-conditioned media for NF-κB. The B cell NF-κB reporter with elevated basal activity was further tested with an NF-κB inhibitor. In addition, all reporters were evaluated in co-culture with primary immune and cancer cells. Results: Stimuli activating NFAT or NF-κB signaling produced strong, dose-dependent increases in luciferase activity, while pathway inhibition reduced signal as expected. Co-culture with primary immune and cancer cells generated diverse activation patterns, reflecting context-dependent signaling shaped by interactions within the TME. Conclusions: These reporter cell lines provide a scalable platform for monitoring NFAT- and NF-κB-driven immune activation across T, B, and myeloid lineages. They support sensitive, reproducible evaluation of immune responses, enable mechanistic studies of dynamic immune crosstalk, and evaluation of combinatorial immunotherapy strategies within the TME. Citation Format: Hyeyoun Chang, John G. Foulke, Luping Chen, Meghan Sikes, Catherine McManus, Fang Tian, . Immune signaling reporter cell lines enable quantitative monitoring of crosstalk among cancer, innate, and adaptive immune cells in tumor microenvironment model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4928.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-4928
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4928: Immune signaling reporter cell lines enable quantitative monitoring of crosstalk among cancer, innate, and adaptive immune cells in tumor microenvironment model

Hyeyoun Chang, Catherine E. McManus, Meghan C Sikes, Luping Chen et al.
Cancer Research
Cancer Immunotherapy and Biomarkers
article

Abstract 4928: Immune signaling reporter cell lines enable quantitative monitoring of crosstalk among cancer, innate, and adaptive immune cells in tumor microenvironment model

Hyeyoun Chang, Catherine E. McManus, Meghan C Sikes, Luping Chen, Fang Tian, John G. Foulke
article en

Abstract

Abstract Background: T cell-targeted immunotherapies have led to major clinical gains, yet many patients fail to respond or develop resistance due to the immunosuppressive tumor microenvironment (TME). Increasing evidence shows that B cells and myeloid cells also influence antitumor immunity, but accessible models capable of capturing interactions among cancer cells and multiple immune cell types remain limited. To address this gap, we developed immune signaling reporter cell lines that allow real-time, quantitative monitoring of NFAT- and NF-κB-driven activation pathways. These models enable capturing dynamic interactions among multiple immune cell lineages and cancer cells relevant to immunotherapy response. Methods: Six luciferase-based reporter lines derived from T cells, B cells, or myeloid cells were engineered with NFAT or NF-κB response elements driving luciferase expression. The models retain high endogenous expression of checkpoint receptors, including PD-1, TIGIT, and GITR in T cell reporters and SIRPα, Siglec-10, LILRB1, and B7-1 in myeloid reporters. Reporter activation was assessed following pathway-specific stimulation: PMA and ionomycin for NFAT and TNF-α or T cell-conditioned media for NF-κB. The B cell NF-κB reporter with elevated basal activity was further tested with an NF-κB inhibitor. In addition, all reporters were evaluated in co-culture with primary immune and cancer cells. Results: Stimuli activating NFAT or NF-κB signaling produced strong, dose-dependent increases in luciferase activity, while pathway inhibition reduced signal as expected. Co-culture with primary immune and cancer cells generated diverse activation patterns, reflecting context-dependent signaling shaped by interactions within the TME. Conclusions: These reporter cell lines provide a scalable platform for monitoring NFAT- and NF-κB-driven immune activation across T, B, and myeloid lineages. They support sensitive, reproducible evaluation of immune responses, enable mechanistic studies of dynamic immune crosstalk, and evaluation of combinatorial immunotherapy strategies within the TME. Citation Format: Hyeyoun Chang, John G. Foulke, Luping Chen, Meghan Sikes, Catherine McManus, Fang Tian, . Immune signaling reporter cell lines enable quantitative monitoring of crosstalk among cancer, innate, and adaptive immune cells in tumor microenvironment model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4928.

Cancer ResearchVol. 86(7_Supplement)
American Type Culture Collection (US)
Good health and well-being
Openalex Percentile: Top 10%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.